Inozyme Pharma Inc reports results for the quarter ended in December - Earnings Summary

Inozyme Pharma

22/03/2023 14:09

* Inozyme Pharma Inc  INZY.OQ  reported a quarterly adjusted
loss
of 42 cents​​ per share for the quarter ended in December. The
mean expectation of seven analysts for the quarter was for a
loss of 45 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inozyme Pharma Inc's reported EPS for the quarter was a
loss
of 42 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Inozyme Pharma Inc shares had risen by 189.5% this
quarter.
    * The company reported a quarterly loss of $18.54 million.
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 22 at 02:09 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.45          -0.42          Beat
 Sep. 30 2022      -0.43          -0.38          Beat
 Jun. 30 2022      -0.48          -0.38          Beat
 Mar. 31 2022      -0.82          -0.71          Beat